Bakhoum, Mathieu F.
Francis, Jasmine H.
Agustinus, Albert http://orcid.org/0000-0002-2700-6475
Earlie, Ethan M. http://orcid.org/0000-0003-3039-9692
Di Bona, Melody http://orcid.org/0000-0002-8853-2604
Abramson, David H.
Duran, Mercedes
Masilionis, Ignas http://orcid.org/0000-0001-7937-9014
Molina, Elsa
Shoushtari, Alexander N. http://orcid.org/0000-0002-8065-4412
Goldbaum, Michael H.
Mischel, Paul S. http://orcid.org/0000-0002-4560-2211
Bakhoum, Samuel F. http://orcid.org/0000-0002-4779-8422
Laughney, Ashley M. http://orcid.org/0000-0001-9435-953X
Funding for this research was provided by:
Melanoma Research Alliance
Burroughs Wellcome Fund
Article History
Received: 25 May 2020
Accepted: 17 August 2021
First Online: 13 September 2021
Competing interests
: S.F.B. holds a patent related to targeting CIN and the cGAS-STING pathway in advanced cancers. He owns equity in, receives compensation from, and serves as a consultant for and on the Scientific Advisory Board and Board of Directors of Volastra Therapeutics Inc. He has also consulted for Sanofi. PSM is a co-founder of Boundless Bio, Inc. He has equity interest in the company and serves as the chair of the Scientific Advisory Board. All other authors declare no competing interests.